Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.5.1426 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11870192 Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas Nicolas MounierxNicolas MounierSearch for articles by this author , Daniele SimonxDaniele SimonSearch for articles by this author , Corinne HaiounxCorinne HaiounSearch for articles by this author , Philippe GaulardxPhilippe GaulardSearch for articles by this author , Christian GisselbrechtxChristian GisselbrechtSearch for articles by this author Issa KhourixIssa KhouriSearch for articles by this author Show More Groupe d’Etude des Lymphomes de l’Adulte, Hôpital Saint Louis AP-HP, Paris, FranceM.D. Anderson Cancer Center, Houston, TX https://doi.org/10.1200/JCO.2002.20.5.1426 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse01032002In Reply:A prospective randomized study of conventional chemotherapy (CT) versus CT followed by autologous stem-cell transplantation was started at M.D. Anderson Cancer Center in 1985 for patients with poor-risk, aggressive lymphoma having a tumor score of ≥ 3.1 Patients were randomized before starting any treatment. Those randomized to the nontransplantation arm received nine courses of alternating IdSHAP (idarubicin, cytarabine, and cisplatin), MBIDCOS (idarubicin, cyclophosphamide, vincristine, bleomycin, and solumedrol) and MINE (mesna, ifosfamide, mitoxantrone, and etoposide). Patients randomized to the transplantation arm received two courses of chemotherapy (IdSHAP and MBIDCOS) and then, if they responded, they received a course of ifosfamide/etoposide for stem-cell mobilization followed by autologous stem-cell transplantation with BEAM (carmustine, etoposide, cytarabine, and melphalan). Seventeen patients with PTCL were included. An interim intent-to-treat analysis has shown that seven (70%) of 10 patients who received high-dose chemotherapy are alive versus two (28.5%) of seven patients who were randomized to the nontransplantation arm (P = .08). This is another proof of principle that high-dose chemotherapy can potentially overcome the poor prognosis associated with T-cell immunophenotype (R.E. Champlin, personal communication, October 2001).REFERENCE1. Rodriguez J, Cabanillas F, McLaughlin P, et al: A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the tumor score. Ann Oncol 3:: 711,1992-717, Crossref, Medline, Google Scholar